1. Home
  2. AVX vs PMVP Comparison

AVX vs PMVP Comparison

Compare AVX & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AVX

Avax One Technology Ltd.

N/A

Current Price

$0.60

Market Cap

63.3M

Sector

Industrials

ML Signal

N/A

Logo PMV Pharmaceuticals Inc.

PMVP

PMV Pharmaceuticals Inc.

HOLD

Current Price

$1.49

Market Cap

73.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AVX
PMVP
Founded
2017
2013
Country
Canada
United States
Employees
3
N/A
Industry
Metal Fabrications
Medicinal Chemicals and Botanical Products
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
63.3M
73.1M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
AVX
PMVP
Price
$0.60
$1.49
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
337.2K
441.8K
Earning Date
05-14-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.47
$0.83
52 Week High
$2.27
$1.88

Technical Indicators

Market Signals
Indicator
AVX
PMVP
Relative Strength Index (RSI) 46.53 60.10
Support Level $0.55 $1.37
Resistance Level $0.84 $1.53
Average True Range (ATR) 0.07 0.08
MACD 0.01 0.02
Stochastic Oscillator 47.79 100.00

Price Performance

Historical Comparison
AVX
PMVP

About AVX Avax One Technology Ltd.

AVAX One Technology Ltd is a public company offering investors regulated access to the Avalanche (AVAX) ecosystem. By integrating the reliability of U.S. capital markets with the growth potential of decentralized finance, it seeks to create a bridge between traditional and digital finance. The company focuses on building a digital-asset treasury, fostering innovation, and investing in decentralized financial technologies that benefit from the Avalanche network.

About PMVP PMV Pharmaceuticals Inc.

PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.

Share on Social Networks: